EMA proposes updating guideline for Alzheimer’s disease treatments
EMA proposes updating guideline for Alzheimer’s disease treatments | RAPS
Regulatory NewsJoanne S. Eglovitch
Chemistry, Manufacturing and Controls (CMC)Clinical TrialsEuropeEuropean Medicines Agency (EMA)PharmaceuticalsProduct developmentProduct LifecycleRegulatory Intelligence/PolicyRegulatory strategySubmission and registration